Risks and benefits of periodic treatment of asthma with inhaled corticosteroids.

BioDrugs

Departments of General Practice/Family Practice, University of Nijmegen and University of Maastricht, The Netherlands.

Published: January 1997

AI Article Synopsis

  • It is crucial to assess if inhaled corticosteroids can be stopped during stable asthma phases, as most studies suggest they cannot.
  • A study involving 14 corticosteroid-dependent asthma patients showed no significant difference in lung function (FEV(1)) when corticosteroids were discontinued after 2 years of treatment.
  • Findings suggest that some patients with mild asthma might safely use inhaled corticosteroids intermittently rather than continuously.

Article Abstract

It is important to determine whether inhaled corticosteroids can be discontinued during a stable phase of asthma. So far, most studies have shown that it is not possible to discontinue medication. We studied 14 patients with corticosteroid-dependent asthma who had shown a decline in forced expiratory volume in 1 second (FEV(1)) of at least 80 ml/year and at least 1 exacerbation per year during 2 years of bronchodilator treatment. Patients were then treated additionally with inhaled corticosteroids for another 2 years and were then given the option to discontinue corticosteroids. The course of FEV(1) during the year in which corticosteroids were discontinued was not significantly different from that in the 2-year period of corticosteroid treatment. Furthermore, there was no change in other lung function parameters, symptom score or exacerbation rate. Discontinuing inhaled corticosteroids might be possible in some patients with asthma after 2 years of regular treatment. This may indicate that, for certain groups of patients with mild asthma, periodic treatment with inhaled corticosteroids is the treatment policy for the future.

Download full-text PDF

Source
http://dx.doi.org/10.2165/00063030-199707010-00001DOI Listing

Publication Analysis

Top Keywords

inhaled corticosteroids
20
periodic treatment
8
corticosteroids discontinued
8
corticosteroids
7
treatment
6
asthma
5
inhaled
5
risks benefits
4
benefits periodic
4
treatment asthma
4

Similar Publications

Results from a UK consensus about the optimal prescribing of medium strength triple therapy in uncontrolled adult asthma patients in the NHS.

J Family Med Prim Care

December 2024

Medicines Evaluation Unit, Manchester University National Health Service Foundation Trust, University of Manchester, Manchester, United Kingdom.

Context: An inhaled corticosteroid (ICS) in combination with a long-acting β2-agonist (LABA) is a common treatment approach for asthma patients not controlled on ICS alone, but a significant proportion of patients remain uncontrolled on this combination and treatment adherence can also be a challenge. One of the options for adults whose asthma is uncontrolled in an ICS/LABA is the addition of a long-acting muscarinic receptor antagonist (LAMA), an approach commonly referred to as 'triple therapy'. The use of medium-strength ICS/LABA/LAMA is established in treating chronic obstructive pulmonary disease but is less well-established in asthma.

View Article and Find Full Text PDF

Background: Biologics can induce remission in some patients with severe asthma, however, little is known about pre-biologic disease trajectories and their association with outcomes from biological treatment. We aimed to identify long-term trajectories of disease progression in patients initiating biologics and investigate trajectory associations with disease burden and impact on biologic therapy efficacy.

Methods: Patients in the Danish Severe Asthma Registry initiating biologic therapy between 2016-2022 were included and followed retrospectively in prescription databases starting 1995.

View Article and Find Full Text PDF

Objective: It remains unclear whether baseline FENO levels can predict response to anti-IL5/5R biologic treatment in patients with severe asthma.

Methods: We recruited 104 patients with severe eosinophilic asthma treated with anti-IL5/anti-IL5R for at least one year who had measured FeNO values before the beginning of anti-eosinophilic treatment. Population was divided into subjects with FeNO < 25 and ≥25 ppb.

View Article and Find Full Text PDF

Background/aims: Chronic obstructive pulmonary disease (COPD) management guidelines have increasingly emphasised the importance of exacerbation prevention, and the role of blood eosinophil count (BEC) as a biomarker for inhaled corticosteroids (ICS) response. This study aimed to describe the distribution and stability of BEC and understand real-world treatment patterns among COPD patients in South Korea.

Methods: This was a retrospective database analysis using data obtained from the KOrea COPD Subgroup Study (KOCOSS) registry between January 2012 and August 2018.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!